Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (ASND) and increased the price target from $196 to $260.
March 15, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's stock rating was maintained at Overweight by Wells Fargo, with the price target raised from $196 to $260.
The increase in price target by a reputable analyst like Derek Archila suggests a strong confidence in Ascendis Pharma's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in ASND's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100